I am very pleased to report that UW researchers have received a grant from the National Institutes of Health (NIH) to test a promising, novel surgical therapy for treating idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive lung disease of unknown cause and increasing prevalence in the United States. An estimated 100,000 Americans die from IPF each year, typically within three to five years of diagnosis.
The disease is characterized by development of excess fibrous tissue in the lungs. Aside from lung transplantation, which only one percent of affected patients receive, there is no FDA-approved therapy. The grant brings new hope for slowing progression of a fatal disease through safe, minimally invasive surgery.
Read the entire article at: